Actinium Pharmaceuticals, Inc(NYSE MKT:ATNM) 
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a ...
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-03
P
O 1.43
H 1.50
L 1.36
C 1.39
V 291,738
10EMA 1.39
20EMA 1.39
60EMA 1.39
120EMA 1.39
250EMA 1.39